VHL and nonpapillary renal cell carcinoma: The prevalence of having any VHL alteration (i.e. inactivating, silent, and intronic mutations, and promoter hypermethylation) was 83.0% among all RCC cases, 88.3% among the subset of ccRCC cases, and 16.2% among non-ccRCC cases (Table 1).